“CFI-400945 PLK4 Inhibitor Efficacy in Relapsed/Refractory AML and Higher-Risk MDS, Particularly in TP53 Mutated Patients: Phase 1 Study Results”

https://pubmed.ncbi.nlm.nih.gov/38114624

CFI-400945, a PLK4 inhibitor, shows efficacy in treating relapsed/refractory AML and higher-risk MDS, particularly in TP53 mutated patients, with acceptable safety profile in a phase 1 study.